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Medication management training for mental health professionals– A 
programme of research  
 
Abstract: 
Aim 
This research programme aimed to investigate issues relating to the management of patient non-
adherence with antipsychotic medication.  The findings from the patient-related studies and the 
systematic literature review informed the development of a medication management staff training 
programme; which was evaluated in terms of the effects on mental health professionals’ 
understanding and clinical practice in Hong Kong. 
 
Background 
Medication management interventions which are designed to maximise the potential benefits of 
antipsychotic medication for severe mental illness have shown promise in improving symptoms, 
reducing relapse rates and addressing non-adherence. Subsequent medication management studies 
which involve training mental health professionals in similar psychosocial interventions have also 
demonstrated that improvements in mental health professionals’ knowledge, attitudes and skills can 
result in improved patient outcomes; however, the studies have not been replicated outside 
western general psychiatry settings and therefore the effects of training mental health professionals 
in other clinical contexts have not been established. 
 
Methods 
This research programme consists of a series of five studies that utilised a variety of methodological 
approaches. Three cross-sectional surveys were used to identify and explore clinical problems 
central to medication management in order to refine the staff training programme; the first 
investigates the extent of, and associations with, antipsychotic medication non-adherence in prisons. 
Qualitative interview data from the prison study provides additional context to the requirements for 
medication management training interventions by exploring prisoners’ experiences of taking 
antipsychotic medication. The second survey ascertains and explores the problem of non-adherence 
with antipsychotics in an Asian population, and the third provides an estimate of potential 
treatment-related physical health problems. A systematic literature review investigates studies 
which measure the effects of medication management training on clinicians’ knowledge, attitudes 
and skills. Finally concept mapping and clinicians’ narratives are used in a longitudinal case series 
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study in order to establish the transferability of medication management training to an Asian setting 
and evaluate the effects of training on clinicians’ understanding and clinical practice.  
 
Results 
Patients’ positive attitudes towards antipsychotic medication, particularly awareness of the need for 
treatment predicted higher levels of adherence, and concerns about the adverse effects of these 
medications are closely related to the environmental context of treatment.  Concerns associated 
with antipsychotic side effects appear to be less prominent when patients are not working or in 
prison but they may influence adherence when demands on functioning change. The modified 
medication management training was effective in improving clinicians’ understanding and was felt to 
be transferrable to an Asian setting, but patients’ and families’ traditional cultural beliefs about 
mental illness and concerns about the effects of western medication on physical health were found 
to be particular challenges when implementing adherence interventions. Patients with severe 
mental illness in Hong Kong are twice as likely compared to the general population to have 
developed metabolic syndrome, consequently medication management interventions could require 
greater focus on the identification and management of physical health problems; which may help to 
address patient and family concerns about long-term treatment. The staff training programme 
requires psychopharmacology teaching, provision of clinical supervision and side effects 
management content in order to improve clinicians’ confidence when implementing medication 
management interventions.  
 
Conclusions 
Concerns about the adverse effects of treatment that influence adherence are environmentally 
bound.  As influences on medication adherence are different in different settings, staff training 
programmes should place more emphasis on the local context in order to improve efficacy and the 
feasibility of implementation. The results suggest that in Hong Kong medication management 
interventions should have an increased focus on families and that treatment satisfaction could be a 
suitable target for interventions. The findings also present a question about whether previous 
medication management studies have given due consideration to predicting and managing concerns 
about the impact of side effects on functioning over the longer term and the potential effects of 
medication on patients’ physical well-being. The outcomes of this programme also demonstrate that 
future medication management training studies need to use robust study designs in order to more 
certainly attribute clinicians’ improvements to the training intervention and could consider 
measuring treatment satisfaction as a primary patient outcome measure. 
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Medication management training for mental health professionals– 
A programme of research  
 
1:  Introduction 
This programme of research investigates issues that are central to medication management for 
severe mental illness.  The first study explores patient-related factors that are associated with 
antipsychotic treatment adherence in a population of UK based prisoners.  Two subsequent surveys 
investigate antipsychotic treatment adherence and the extent of treatment-related physical health 
problems in a community sample of people with severe mental illness in Hong Kong. The results of a 
systematic review and the earlier studies are then used to inform the development of a medication 
management staff training programme, which is evaluated in terms of the impact on Hong Kong 
based community mental health professionals’ understanding and clinical practice. The studies 
involve a combined total of 767 patients and 26 clinicians.  
The following definitions of terminology apply throughout this commentary: 
Medication management (clinical) interventions:  
Any psychosocial therapeutic intervention designed to be used by mental health 
professionals with individual patients to help them manage their medication for severe and 
enduring mental illness. 
Medication management training interventions: 
Educational or training interventions provided to mental health professionals which aim to 
improve their ability to manage medication for severe and enduring mental illness. 
Intervention target(s): 
The focus of medication management interventions used by mental health professionals 
when working with individual patients. 
1:1 The research programme rationale 
A number of other researchers have tested the effectiveness of implementing medication 
management interventions for people with severe mental illness (SMI) into routine clinical practice 
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by providing medication management staff training programmes.  The outcomes have been 
measured in terms of patients being treated and the impact of training on clinicians’ knowledge, 
attitudes and skills in managing medications and associated non-adherence. The training trials have 
produced some positive results in general mental health settings in Australia, USA and the UK (i.e. 
Gray, et al., 2004; Harris et al., 2009; Byrne et al., 2010; Byrne and Deane, 2011), but the studies 
have not been replicated outside these environments and therefore the effects of training mental 
health staff in other clinical settings have not been established.   
 
In order to investigate whether similar targets for medication management interventions exist 
across different clinical settings, this programme of research focuses on two clinical areas in which 
there is a lack of evidence about influences on adherence and the effects of treatment for SMI on 
physical health.  The clinical environments that were investigated were UK prisons and a Community 
Psychiatric Nursing Service in Hong Kong.  Being able to understand these issues would provide 
evidence that is required to refine the content of staff medication management training 
programmes in order that clinical medication management interventions could become more 
sophisticated in accordance with the clinical context.    
 
This reflective commentary critically analyses each study and aims to demonstrate the process of 
adapting a medication management staff training intervention based on both new evidence and 
piloting of the use of the approaches in clinical practice. 
 
1:2 Aims and objectives: 
 
Aims: 
 • This research programme aimed to investigate issues relating to the management of patient 
non-adherence with antipsychotic medication.  The findings from the patient-related studies 
and the systematic literature review informed the development of a medication 
management staff training programme; which was evaluated in terms of the effects on 
mental health professionals’ understanding and clinical practice in Hong Kong. 
 
Specific research questions of each published study in relation to the research programme aims:  
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• What is the extent of and associations with, medication non-adherence in prisons?  (Prison 
adherence survey; Gray et al. 2008) • What do prisoners’ narratives further tell us about adherence and medication management? 
(Prisoners’ experiences study; Mills et al.,2011 ) • How common is antipsychotic medication non-adherence in an Asian population and are 
targets for interventions different in this context? (Hong Kong adherence survey– 
Bressington et al.,2012a) • What are the effects of medication management training on staff outcomes?  (A systematic 
review of the literature; Bressington et al.,2013a)  • How transferrable is medication management training to an Asian population and what 
further modifications to training are required? (Hong Kong training study; Bressington et al., 
2012b) • What is the extent of treatment related metabolic disorders and other physical health 
problems in Hong Kong and how relevant are these issues in managing medication over the 
longer term? (Hong Kong physical health study– Bressington et al., 2013b) 
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2: The research context 
 
2:1 What is medication management for severe mental illness and why is it important? 
 
Medication management 
 
There are a number of different definitions of medication and medicines management which vary in 
relation to professional paradigms. The focus of “medicines management” is on the mechanisms 
that underpin the whole system of prescribing, dispensing, storing, ordering and administering 
medication in order to minimise errors and improve patient safety (Rich, 2004). “Medication 
management” however, has more emphasis on working collaboratively with patients in order to 
maximise their potential response to treatment (Harris et al., 2009a). As mental health clinicians are 
expected to build effective ongoing therapeutic relationships with patients that they work with, they 
are well-placed to help maximise the potential benefits of medication (Usher and Arthur, 1997) and 
therefore this programme focuses on medication management interventions for individuals rather 
than system-related issues. These views are supported by the UK’s Nursing and Midwifery Council’s 
standards for general medication management (NMC, 2007) which broadly suggest that mental 
health clinicians who manage patients medication should assess and evaluate four areas of 
medication outcomes: symptoms, safety, side effects and satisfaction (Gray et al., 2009a).  
 
Managing medication for people with severe mental illness (SMI) is an extremely important role for 
mental health clinicians as patients are often required to take antipsychotics for long periods. 
Helping patients to manage their medication may help to improve treatment efficacy, reduce 
relapse rates, provide the foundations for recovery-focussed psychosocial interventions and reduce 
the financial costs of treatment (Haynes et al. 2008; Harris et al., 2009a). Clearly, if medications are 
not taken it is certain that they will not work to help patients recover. Therefore there are specific 
issues relating to SMI and its treatment that require consideration when constructing medication 
management interventions for this client group.  
 
Severe mental illness 
 
Perhaps the most widely accepted definition of SMI is that patients need to be diagnosed with a 
non-organic psychosis, which has required treatment for at least two years and which has caused 
disruption to the person’s day-to-day functioning (Ruggeri et al.,2000).  The most common diagnoses 
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that fall within this classification are schizophrenia, bipolar spectrum disorders and schizoaffective 
disorder.    
 
Estimates of the prevalence of SMI vary across the world and are complicated by differing definitions 
of the range of conditions that fall within this group of disorders (Ruggeri et al., 2000). The most 
widely studied prevalence rates are those of schizophrenia; with average estimates of world-wide 
lifetime prevalence being in the region of 4 per 1,000 people (Bhugra, 2005), whilst  the annual 
period prevalence rates for psychosis in the UK have been reported as being between 2 and 9 per 
1000 people (Wiles et al., 2006).  
 
Treatment for severe mental illness 
 
The UK’s National Institute for Health and Care Excellence produce guidelines for the treatment of 
SMI such as schizophrenia (NICE, 2009), recommending that treatment should consist of a package 
of care that includes both psychosocial and pharmacological approaches. The pharmacological 
treatments are the main focus of this research programme and they are an essential component as 
they provide symptom stability so that psychosocial interventions can be used to further patients’ 
recovery. Detailed expert consensus guidelines published by the British Association of 
Psychopharmacology (Barnes et al., 2011) explore a wider range of evidence relating to the medical 
treatment of schizophrenia; the authors conclude that antipsychotic medications are core 
treatments throughout all stages of psychosis and should be taken consistently in order to realise 
the potential benefits.       
 
There is a vast amount of evidence that the symptoms of people with SMI can respond positively to 
antipsychotic medications and therefore these are widely used to help patients manage their 
conditions (Leucht et al., 2012). There are many antipsychotic medications available and each class 
of drug is associated with its own benefit and risk profile. The original antipsychotics were first used 
widely in the 1950s and are commonly referred to as first generation or typical antipsychotics.  They 
are effective in managing the positive symptoms of psychosis, but are associated with some 
distressing side effects such as movement disorders and sexual dysfunction (Miyamoto et al., 2012).  
More recently a range of newer antipsychotics have been developed; these second and third 
generation (or atypical) antipsychotics are equally effective in treating positive symptoms, but are 
far less likely to cause movement disorders due their pharmacodynamics (Davis et al., 2003). Despite 
the reduced likelihood of movement disorders some of the atypical antipsychotics have been shown 
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to be associated with sedation and physical health problems which include weight gain and other 
metabolic disorders (Saddichha et al., 2007).  
 
 
2:2 Which elements of medication management should clinicians address? 
A model of antipsychotic medication management in SMI proposed by Usher and Arthur (1997) 
highlights that approaches need to maximise the desired treatment effects, minimise the undesired 
effects, facilitate patient advocacy and adopt a patient empowerment stance. They suggest that 
because the process is often complex and ongoing, the relationship between clinician and patient is 
crucial. Harris et al., (2009a) concur that a collaborative relationship is key and outline the areas of 
medication management for mental health that require greatest consideration, including: 
empowering patients through choice, assessing and managing response to treatment, promoting 
patient safety and working to address both intentional and unintentional adherence problems. 
Adherence issues are central to medication management interventions; however it is important to 
note that patients should be supported in a decision to stop taking medication where a conscious 
and informed choice is being made (NICE, 2009a).  
 
2:3 How common is non-adherence with treatment for severe mental illness and how is this 
best addressed in medication management training? 
 
Treatment adherence is defined as the extent to which a person’s behaviour coincides with 
healthcare professional’s recommendations; such as taking medication as prescribed (Dunbar-Jacob 
and Mortimer-Stephens, 2001). Non-adherence with treatment for all long- term conditions 
(physical or mental health) is extremely common; the average rates are estimated to be around 50% 
(Haynes et al., 2008). The reported rates of non-adherence with antipsychotic medication vary in 
accordance with the clinical setting and the method of measurement, but it is generally accepted 
that around 50% of patients are likely to not take their medication as prescribed and the problem of 
non-adherence persists despite the widespread prescribing of atypical antipsychotics which were 
initially thought to be better tolerated than the typical antipsychotics (Dolder et al., 2003). 
Dichotomising adherence also complicates estimates of prevalence as adherence behaviours are 
unlikely to be static in that they can change on a regular basis (Valenstein et al., 2006).   
 
11
The clinical consequences of non-adherence in SMI are extremely negative; patients that do not take 
their antipsychotic medications are much more likely to relapse, attempt suicide, be admitted to 
hospital and exhibit aggressive behaviours (Byerly et al., 2005).  Even in patients newly diagnosed 
with psychosis the likelihood of relapse in non-adherent patients is 10 times that of adherent 
patients (Morken et al., 2008). Studies have also demonstrated that non-adherence in SMI is 
associated with a three-fold increase in financial treatment costs (Almond et al., 2004).  
 
Influences on adherence  
 
Influences on adherence are well-documented in western general psychiatry settings; these factors 
are potential targets for clinical intervention and have been useful in informing the construction of 
evidence-based interventions that aim to improve adherence with treatment. The influences on 
adherence have been broadly classified into six areas: illness-related factors, treatment-related 
factors, clinician-related factors, patient-related factors, environmental factors and cultural factors 
(Gray et al., 2008). Despite these areas all being important potential influences on medication 
adherence, the specific influences have been shown to vary in accordance with the treatment 
setting and diagnosis (WHO, 2003). Qualitative research has provided an additional insight into 
patients’ experiences of taking antipsychotics; a study conducted in four European countries showed 
that patients with a diagnosis of SMI report that side effect self-management, the efficacy of 
medication, insight and professional/carer support were the four most important factors that 
influenced their adherence to antipsychotic medication (Kikkert et al., 2006). 
 
A theoretical model that is widely referenced and which aims to explain treatment non-adherence 
and target adherence interventions is the necessity-concerns framework, which is based on an 
extended self-regulatory model (Horne and Weinman, 1999). The model was initially proposed for 
long term physical health conditions and has more recently been applied to a range of long term 
mental health problems, including depression (Aikens et al., 2005; Brown et al., 2005) and bipolar 
affective disorder (Clatworthy et al., 2007; 2009).  The model considers that patients’ levels of 
adherence are determined by their perceptions of how the necessity of treatment balances with 
their concerns about medication, and therefore provides some direction in terms of potential areas 
for clinical interventions. For example, Clatworthy et al., (2009) demonstrated that patients with a 
diagnosis of bipolar affective disorder were most likely to be accepting of treatment if they 
perceived high necessity for and low concerns about medication. The authors suggest that the 
model is a useful platform on which to contextualise adherence, but due to the cross sectional 
12
nature of their research the conclusions are limited to the “here and now”.  However, an earlier 
prospective cohort study conducted over six months (Hunot et al., 2007) reinforces the link between 
treatment concerns and adherence to antidepressants, and also shows that patient preference 
about the choice of antidepressant prescribed is a strong predictor of good adherence.  The findings 
from this longitudinal study therefore also suggest that there needs to be a strong collaborative 
working arrangement in place between clinician and patient in order for treatment concerns and 
preferences to be explored over time. This clinical ethos underpins many of the studies which have 
been conducted in order to improve adherence with treatment in people with mental health 
problems and is reflected in associated clinical guidelines (NICE, 2009a). 
 
Adherence intervention efficacy studies 
 
A number of studies have investigated the efficacy of patient-focussed adherence interventions in 
SMI (i.e. Kemp et al., 1998; O’Donnell et al., 2003; Gray et al., 2006; Staring et al., 2010) and the 
principles underpinning these approaches have more recently been supported by The National 
Institute for Clinical Excellence in the UK (NICE, 2009a) which published clinical guidance on the need 
to use a patient-centred approach which encourages clinicians to facilitate patients’ informed choice 
about adherence.  
 
Interventions to improve adherence are often determined by the intentional or unintentional nature 
of non-adherence. Unintentional non-adherence can relate to misunderstandings about treatment 
or forgetting to take medication; these issues are probably best addressed using practical 
approaches that reduce the complexity of drug regimens or aim to directly change medication taking 
behaviour by using problem solving techniques (Barkhof et al., 2012), or from a pharmacological 
perspective using long acting injections to minimise inconvenience and the frequency of 
administration (Patel et al., 2009). 
 
Addressing intentional non-adherence requires a more complex approach; the most influential study 
to demonstrate the efficacy of psychosocial interventions in improving intentional non-adherence in 
SMI was conducted by Kemp et al., (1998). The study used a randomised controlled trial design to 
test “Compliance Therapy” involving 74 patients; the results showed that in comparison with the 
control group, patients who received compliance therapy had improved insight into their illness, 
more positive attitudes towards treatment, reduced numbers of readmissions, and better treatment 
adherence at 18 months follow-up.  “Compliance therapy” combines motivational interviewing and 
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cognitive-behavioural interventions and consists of three phases which engage patients in 
collaborative discussions about their beliefs and attitudes towards treatment while avoiding 
confrontation and coercion.  
Subsequent to the Kemp et al study, according to a systematic review (Barkhof et al., 2012) there 
have been at least 10 studies published that investigate the effects of similar interventions in an SMI 
population which have produced some equivocal findings. The first replication of this study 
(O’Donnell et al., 2003) compared compliance therapy with non-specific counselling, and concluded 
that compliance therapy was no more effective than the control intervention in improving patients’ 
adherence with treatment. There have been some criticisms of this trial (i.e. David, 2010; Gray et al., 
2010) that mostly relate to concerns about fidelity to the manualised treatment and lack of 
statistical power. The primary outcome measure was a clinician rating of adherence, which also 
presents questions about the accuracy of measurement.  The relevance of adherence as a primary 
outcome is also potentially clinically and ethically dubious; if patients are more adherent with 
treatment that is not effective for them how meaningful is this?  This issue is well illustrated by a 
more recent randomised-controlled trial of “Treatment Adherence Therapy” (Staring et al., 2010) 
which targeted likely causes of non-adherence in each individual patient and found that although 
there were improvements in adherence, symptoms did not improve.  
 
In terms of efficacy some “Adherence Therapy” controlled trials (based on compliance therapy 
approaches) demonstrate positive outcomes for patients in terms of reduced symptoms (i.e. 
Maneesekorn et al., 2007; Schulz et al., 2013). Whilst others have reported mixed results; Anderson 
et al., (2010) concluded in a small exploratory trial that adherence therapy did not have significant 
effects on symptoms or adherence, but patients engaged actively in treatment. Similarly, Byerly et 
al., (2005a) conducted a trial of adherence therapy in outpatients with schizophrenia and report that 
although adherence improved post-intervention the improvements were not maintained at follow-
up.  The largest randomised controlled trial to date of adherence therapy conducted by Gray et al. 
(2006) compared the intervention to an active control (health education) and concluded that 
adherence therapy was no more effective than the control intervention in improving quality of life. 
The potential reasons for the mixed findings are numerous (David, 2010; Gray et al., 2010); 
measuring adherence is notoriously unreliable, some studies had active control interventions whilst 
others compared to treatment as usual, levels of adherence were often relatively high at baseline 
and the intervention was delivered in varying clinical settings with patients at different stages of 
recovery. 
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The existing evidence therefore indicates that within research settings patient-focussed adherence 
interventions have the potential to improve patient outcomes. However, a more recent review of 
interventions to improve adherence with treatment in SMI (Barkhof et al., 2012) suggests that the 
ongoing and potentially continuous management of adherence may be best carried out by clinicians 
involved in patients’ day-to-day clinical care which appears to reinforce the need for medication 
management staff training in order to equip the workforce to implement interventions within 
everyday clinical practice. 
 
2:4 What are the potential benefits of medication management staff training for patient 
outcomes?  
Staff training has the potential to improve patients’ outcomes because research has demonstrated 
that there is a relationship between clinician knowledge and attitudes relating to medication 
management and ability to address non-adherence issues in SMI (Byrne et al., 2005; Byrne and 
Deane, 2011).  A more recent study also supports the need for staff training; the relationship 
between staff knowledge/skills and difficulties managing medication non-adherence for bipolar 
affective disorder was reported by Tacchi et al., (2012) who showed that clinicians’ baseline 
knowledge about medication and adherence in BPAD was poor and that the clinical approaches 
being used in an attempt to manage nonadherence were unlikely to be effective.  
 
The previous medication management staff training trials have all demonstrated consistently 
positive patient outcomes and seem an appropriate and effective way to maximise the potential of 
medications and reduce non-adherence. The studies show that training community-based mental 
health care professionals resulted in improvements in symptoms of their patients, increased levels 
of adherence and improved patient engagement (Gray et al., 2004; Byrne and Deane, 2011; Harris et 
al., 2009). However; the study designs, contents, duration and effectiveness of the medication 
management staff training interventions vary across the different studies.  
 
Gray et al., (2004) conducted a cluster randomised controlled trial in the UK which involved 60 
community mental health professionals (CMHPs) and measured the effects of staff training on 
patients’ psychopathology and other clinical outcomes over a six month period. The nurses were 
randomised based on geographical clusters to receive 80 hours of medication management training 
or to continue to provide treatment as usual. The results show that patients being treated by CMHPs 
who had received the training had significantly reduced levels of symptoms compared the treatment 
as usual group (change in PANSS total scores: medication management -16.62, treatment as usual 
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1.17; difference -17.79; 95% CI -24.12 to -11.45; P<0.001).  The improvement in psychopathology is 
clinically significant as 6 of the patients in the medication management group achieved at least a 
30% reduction in symptoms compared to none in the treatment as usual group. 
 
In addition to psychopathology, patients in the medication management group also showed a 
significant improvement in attitudes towards treatment and adherence with medication in 
comparison to treatment as usual. The training involved teaching “Compliance Therapy” 
interventions (as described by Kemp et al., 1996), training in the use of standardised measures to 
assess side effects/treatment attitudes and basic psychopharmacology education. The results 
suggest that the positive results seen in Kemp et al’s (1998) “Compliance Therapy” trial can be 
replicated in routine clinical practice by providing the workforce with medication management 
training.    
 
Harris et al., (2009) also conducted a cluster randomised controlled trial in the UK.  Their study 
involved randomising 28 pairs of CMHPs to either medication management training or treatment as 
usual. Similarly to the Gray et al (2004) study the training lasted for 10 days, however the 
researchers also provided monthly individual clinical supervision over the 9 month duration of the 
study. The contents of the training programme resembled those of Gray et al (2004); however there 
was some variation in the outcome measures and the clinical interventions had greater focus on 
reviewing the effectiveness of prescribed medications. The study also placed greater emphasis on 
the relationships between service users and CMHPs by assessing service users’ perception of 
therapeutic involvement using the Californian Psychopharmacology Alliance Scale (CALPAS) (Gaston 
and Marmar, 1993). The results of this study show significant improvements in psychopathology and 
the CALPAS scores for the patients being treated by CMHPs who had received training when 
compared to the control group. 
 
Similarly, Byrne and Deane (2011) conducted a “medication alliance” 3 day staff training programme 
in Australia. The patients being treated by 46 CMHPs that received the educational intervention 
were followed over a period of 12 months and the patient outcomes measured included medication 
adherence, attitudes towards treatment, psychopathology and insight. The researchers suggest that 
the training programme resulted in significant improvements in levels of patients’ adherence and 
psychopathology, but as this is an uncontrolled study caution needs to be applied when interpreting 
the findings. Despite the study limitations, the results are promising and indicate that a shorter 
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medication management training programme can result in improved patient outcomes in a similar 
fashion to the longer training programmes.   
 
The findings from all the previous medication management training studies therefore highlight that 
improving the knowledge and skills of CMHPs can result in better patient outcomes; however, due to 
the studies all being carried out in similar cultural and clinical settings it is uncertain as to how 
transferrable the training intervention is to other populations.  
 
2:5 Why may medication management training interventions require adaptation to suit the           
local clinical context? 
 
Researchers have demonstrated that when evidenced-based interventions are delivered to new 
populations they may require adaptation in terms of content, focus and method of delivery (i.e. 
Castro et al., 2004; Bell et al., 2007). A recent study also reinforces the need to alter medication 
management  interventions to suit new cultural settings; Williams et al., (2012) conducted a series of 
mixed-methods studies and highlight the importance of including family members in interventions  
designed to improve adherence to HIV medications in China. It is therefore possible that the 
requirement to adapt adherence and related medication management interventions provides one 
potential explanation for the mixed results of efficacy studies conducted in new populations.  The 
need to fine-tune adherence interventions for new populations is also supported by a literature 
review; Zygmunt et al., 2002 concluded that interventions targeted specifically to problems of non-
adherence were more likely to be effective than broadly focussed interventions.    
 
Transcultural psychiatry research has also demonstrated that the cultural and ethnic context and 
interpretation of mental health problems and their treatment vary dramatically across different 
cultures (Tseng, 2006) and this provides additional rationale for establishing the feasibility of 
adherence interventions in different cultures. A randomised-controlled trial of adherence therapy in 
Thailand (Maneesekorn et al., 2007) is the only study conducted in an Asian setting and is 
encouraging in terms of potential transferability of the intervention to a new cultural group. The 
intervention resulted in the largest effect size of all the previous studies and this clearly 
demonstrates that the intervention can be effective outside western settings. However, the wider 
scale implementation into routine practice via staff training has not been investigated and therefore 
clinicians’ perceptions about the acceptability and relevance of the approach are currently unknown. 
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When expecting clinicians to implement interventions within routine practice it is vital to ascertain 
their views about the acceptability of interventions. This is clearly demonstrated by a recent 
randomised-controlled trial which investigated the efficacy of “Joint Crisis Plans” to reduce 
compulsory treatment for people with psychosis (Thornicroft et al., 2013). The researchers conclude 
that the intervention was not successful as there were no improvements in compulsory admission 
rates in comparison with treatment as usual. However, they also report that the clinicians who 
delivered the intervention had little faith in the approach; they did not maintain fidelity to the 
specified treatment model and less than half of the interventions were delivered in discrete clinical 
sessions as recommended by the study protocol. This raises important questions about the need for 
clinicians to “buy-in” to an intervention in order for it to be effectively and faithfully implemented in 
clinical practice (Thornicroft et al., 2013).       
 
2:6 The sequence, process and coherence of studies included in this research programme 
Appendix 1 is a concept map that details the sequence, process and relationship between the 
studies included in this research programme. The series of studies demonstrate my ongoing 
professional development as an autonomous researcher to the extent where I led three of the five 
included studies.   
The first study commenced in the summer of 2006 and involved a survey by questionnaire and 
concurrent interviews of a sample of prisoners prescribed antipsychotic medication in three UK 
prisons.  The quantitative and qualitative aspects of the study were reported in two separate papers 
(Gray et al. 2008; Mills et al., 2011).   The study was funded by the Prison Health Research Network 
and my involvement started after funding had been granted. I was involved in the final design of the 
study in terms of considering which quantitative measures would be utilised and in finalising the 
semi-structured interview questionnaire. As a more junior member of the research team I worked 
under supervision from the chief investigator and assumed responsibility for the research in one of 
the clinical settings.  In addition to this; I conducted the literature review, obtained research 
governance approval for one site, recruited participants at one site, collected the majority of 
quantitative data, conducted participant interviews, input all quantitative data, jointly analysed data, 
interpreted data analysis, was lead for writing of the quantitative paper and the corresponding 
author. The results from this study indicate that the clinical variables associated with antipsychotic 
medication adherence in prisons differed to those observed in UK community based samples of 
patients with severe mental illness; particularly in relation to the impact of adverse effects of 
medication on levels of adherence. These observed differences suggest that the specific clinical 
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environment is closely related to adherence and highlight the need for further research in similarly 
under-researched populations.  Table 1 (appendix 2) synthesises the quantitative and qualitative 
findings in order to make recommendations for interventions to improve antipsychotic medication 
adherence in prisons.    
The second study is a large survey of community-based patients with severe mental illness in Hong 
Kong (Bressington et al., 2012a) which started in January 2007; this study aimed to identify 
influences on medication adherence in this previously unexplored clinical population by using a 
similar research design to the first study and also adopted a similar data analysis strategy. The study 
explored issues relating to antipsychotic medication adherence and was led by a colleague in Hong 
Kong; I provided advice on the research design, helped with data input/cleaning, jointly analysed 
data, interpreted data analysis, wrote the final paper and was corresponding author. The results of 
this study suggest that levels of non-adherence are significant enough to warrant clinical attention in 
terms of medication management. Similarly to the findings from the quantitative prison study in this 
research programme, positive treatment attitudes were found to be significantly associated with 
adherence; this reinforces the view that interventions to improve adherence need to explore and 
improve patients’ attitudes towards their medication.  
Given that antipsychotic nonadherence was established as a significant clinical problem in Hong 
Kong, the next stage of this research programme was to identify and explore studies which reported 
the effects of staff medication management training on improving mental health professionals’ 
ability to manage this issue. A systematic review of the literature (Bressington et al., 2013a) 
commenced in the summer of 2010, it was conducted in order to clarify which medication 
management training interventions had been most effective; so that both the contents and research 
design of the planned subsequent staff training study were based on the best available evidence.  I 
designed the review, conducted the literature search, jointly assessed the quality of the included 
studies, conducted data analysis, interpreted findings of the review/analysis, wrote the paper and 
was corresponding author. Table 2 (appendix 3) outlines the main results from this review and the 
previous studies which were used to help inform the content and the research design of the 
subsequent medication management training programme.    
The fourth study included in this research programme (Bressington et al., 2012b) is longitudinal case 
series study that investigates the effects of the modified medication management staff training 
programme on community mental health practitioners’ understanding and clinical practice in Hong 
Kong. The study was designed based on the findings from the earlier studies included in this research 
programme and started in 2011. In terms of my involvement I was the project lead, designed the 
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study, wrote the proposal, completed all ethical approval documentation, obtained funding, 
delivered the training, collected concept mapping data, jointly analysed data and was corresponding 
author. It was decided to conduct a longitudinal case series, employ a mixed-methods approach 
towards data collection and collect data at baseline, immediately post training and at 9 months 
follow-up. The primary method of data collection chosen was concept mapping because previous 
research findings (Bressington et al., 2011) suggested that it was a useful method to use to measure 
changes in understanding over time and also was effective to encourage self-prompted reflective 
dialogue within qualitative interviews. The study also used the Knowledge about Medication 
Management Multiple Choice Questionnaire (KMMCQ; Gray et al., 2004) to measure changes in 
clinicians’ knowledge immediately post training in order to be able to compare the results with 
previously published studies.   
 
In line with the recommendations in table 2 (appendix 3) the training programme was delivered for a 
total of five days; the initial three days teaching were followed by a period of three days clinical 
practice before the remainder of the teaching content was delivered. The period of clinical practice 
was built in so that CMHP’s clinical work could be explored through clinical supervision in the 
classroom. We included content relating to psychopharmacology/side effect management due to 
the associations identified between side effects and non-adherence in our Hong Kong adherence 
survey. The compliance therapy interventions used in previously published studies were at the core 
of the clinical approaches that were taught to address non-adherence and the main elements of 
manualised adherence therapy (Gray et al., 2006) were used in an attempt to improve clinician 
fidelity to the treatment protocol; although more emphasis was placed on predicting how the 
adverse effects of treatment may become more concerning if demands on occupational and social 
functioning change over the longer term.  In line with the results from the Hong Kong adherence 
survey, CMHPs were encouraged to explore patients’ views about their awareness of the need for 
treatment so that the primary and secondary benefits of medication may be reinforced. 
 
The final study in this research programme (Bressington et al., 2013b) is a cross-sectional study 
which aimed to estimate the prevalence of metabolic syndrome in community-based patients with 
severe mental illness in Hong Kong and to identify the relationships between metabolic syndrome 
and treatment, sociodemographic and lifestyle factors.  The study commenced in February 2012, the 
rationale for conducting it stemmed from the results from the Hong Kong survey which 
demonstrated that adherence was associated with antipsychotics reported to cause metabolic 
problems and also from the staff medication management training study in which mental health 
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professionals identified family concerns about physical heath as being a barrier to adherence. This 
was an important issue to explore as given the absolute lack of evidence about the extent of 
metabolic disorders in the Hong Kong SMI population, clinicians in this setting would have difficulty 
in providing evidence-based accurate information to concerned patients and carers in relation to this 
issue.  I was the project lead, designed the study, obtained research funding, jointly input data, 
jointly analysed data, interpreted data analysis, wrote the paper and was corresponding author.  
 
The range of studies included in this research programme evolved over time; the process of 
conducting the studies was a learning process where lines of scientific enquiry and research designs 
were influenced by the experiences and results of the previous studies. Therefore the series of 
studies clearly informed each other, but in an ideal world they would have been planned from the 
outset of the programme. With the benefit of hindsight it would have been more effective and less 
time consuming to have engaged the Hong Kong based mental health professionals in focus groups 
prior to designing and delivering the training; this approach may have helped to establish their views 
about their training needs in order that potential barriers to implementation and required 
modifications to content could have been identified earlier. 
 
3: Critical appraisal of included studies 
3:1 General methodological issues 
Quantitative research design of included studies 
The quantitative studies included in this research programme are primarily observational cross 
sectional surveys which were used to establish the extent of clinical problems being investigated and 
identify associated independent variables which may be potential targets for medication 
management interventions. The conclusions drawn from the results obtained from cross sectional 
surveys are limited in that it is not possible to demonstrate causality between the dependent and 
independent variables.  The data that is gathered only provides a snap-shot of the prevalence of the 
dependent variable and other variables that are associated (Hennekens et al., 1987). In addition to 
the limitations on demonstrating causality, cross sectional studies are heavily dependent on the 
recruitment strategy which will influence the generalisability of the results (Barker, 2013).  
Measuring non-adherence with treatment  
 
The measurement of non-adherence is a challenging issue for researchers, particularly as the most 
nonadherent patients are the least likely to agree to participate in studies; potentially resulting in an 
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over-estimation of adherence rates (Gray et al., 2006; David, 2010). Methods of measuring non-
adherence can be classified as being objective or subjective in nature, currently there is no agreed 
gold-standard of measurement, and in fact measurement issues have been cited as being the 
“Achilles Heel” of all adherence research (Kikkert et al., 2008). 
 
Objective measurements include electronic recording of when pill boxes are opened, blood tests to 
ascertain medication levels, medication possession ratios and other pill counting methods (Sajatovic 
et al., 2010).  All of these methods have potential limitations, particularly where non-adherence may 
be covert; for example a record of a pill box being opened or a count of remaining tablets does not 
guarantee that the medication was actually taken. One of the most accurate approaches towards 
objectively measuring adherence (and which may also detect covert non-adherence) is a blood 
serum concentration level to dose ratio (Sajatovic et al., 2010); where higher levels of the ratio 
indicate adherence. However this approach also has limitations in terms of patient acceptability, this 
method was recently utilised as an outcome measure in an adherence therapy randomised 
controlled trial (Shultz et al., 2013) and patients were found to be reluctant to attend for blood tests; 
in fact only 58% of the 161 patients that were randomised for sampling agreed to have their blood 
taken.   
 
Clinicians’ subjective impressions about patients’ levels of adherence have also been shown to be 
potentially inaccurate, particularly when ratings are compared to direct observational methods such 
as medication electronic monitoring systems (Byerly et al., 2007). For example, a study by Byerly et 
al., (2005) reported that clinicians felt 100% of patients were adherent when actually 48% were non-
adherent as measured by the electronic medication monitoring device.   
 
Patients’ subjective reports of adherence levels are similarly problematic and also tend to 
overestimate adherence. Even standardised subjective rating scales that are still widely used in 
adherence research have been shown to have limited accuracy; Kikkert et al., (2008) demonstrated 
that three standardised questionnaires used concurrently in the same patient group (Medication 
Adherence Questionnaire: Morisky et al., 1986; Compliance Rating Scale: Kemp & David, 1996; Drug 
Attitude Inventory: Hogan et al., 1983) failed to agree on levels of non-adherence.  The evidence 
therefore suggests that researchers need to be mindful of the limitations of accuracy that relate to 
adherence measures, appreciate that adherence is likely to be overestimated based on subjective 
reports and where possible combine approaches.  
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Concept mapping as a research method 
Concept mapping is an approach that is used to graphically represent understanding and the process 
of learning; it is based within constructivist epistemology (Kandiko and Kinchin, 2012) and is 
concerned with the ways in which individuals organise and order knowledge based on their 
experiences (von Glasersfeld, 1984). Concept maps are similar to “mind maps” and involve students 
creating a pictorial representation of how concepts relating to their understanding of a particular 
topic are related to each other by using explanatory linking statements (Rice et al., 1998). Recently, 
series of individual concept maps have been used to track the changes (or lack of changes) in a 
person’s understanding over time in order that experiential and other learning triggers can be 
identified and explored (Kinchin et al., 2010; Miller et al., 2009). 
The decision to use concept mapping to explore the process of learning was driven by a review of 
the literature and previous research experience. The evidence base at the time of designing the 
training study suggested that traditional methods of assessing learning (i.e. multiple choice 
questionnaires) were too superficial as they are reliant on comparing students to pre-set academic 
standards, rather than being able explore how new knowledge is integrated into existing 
understanding and how this is actually applied to clinical practice. An example of this finding was 
reported by Hay et al., (2008) who concluded that psychiatry students’ traditional academic 
achievements did not correspond with the complexity of understanding reflected within their 
concepts maps, and also that concept mapping in conjunction with qualitative interviews may elicit 
detailed personal narratives about both the process and outcomes of learning. This view is also 
supported by Miller et al., (2009) who demonstrated that study participants’ reflective narratives 
that were prompted by looking at changes in map series were useful in explaining and expanding the 
researchers’ understanding of the process and results of learning.  
In a previous study Bressington et al., (2011) demonstrated the benefits of using concept maps to 
prompt discussion within interviews and explore how understanding changes as a result of 
education and the application of interventions within clinical settings. Subsequently other 
researchers have suggested that using concept maps and mind maps within qualitative interviews is 
a useful strategy to encourage participant recall and prompt dialogue; Wheeldon (2011) showed 
that research participants who constructed mind maps were more able to remember, organise and 
frame reflections upon their past experiences. Similarly, in a recently published study by Kandiko & 
Kinchin (2012) PhD students completed concept maps and used these within one-to-one interviews 
with their supervisors; the results demonstrated that combining the interview and map data helped 
to reveal the unique nature and process of learning within supervision. 
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3:2 Study 1: What is the extent of and associations with medication non-adherence in 
prisons? And what do prisoners’ narratives further tell us about medication 
management in this setting? 
 (Gray et al., 2008; Mills et al., 2011). 
The critical appraisal of this study is guided by a critical appraisal survey checklist developed by 
Crombie (1996) adapted for the Oxford Centre for Evidence Medicine and published by a British 
Medical Journal evidence based heath series (example questions are in appendix 4). The appraisal of 
the qualitative element of this study is based on the Critical Appraisal Skills Programme Qualitative 
Research Checklist (CASP, 2013a); (please see appendix 5 for examples of questions). 
This study addresses a clearly focused clinical issue as the objectives were to explore the 
relationships between medication adherence and a variety of other clinical/treatment/demographic 
variables in prisoners taking antipsychotic medications. The study also intended to examine 
prisoners’ subjective experiences of medication in order to provide a contextualised understanding 
of adherence within a prison setting.  
The research design seems appropriate for answering the clinical questions as this study utilised a 
mixed methods design where quantitative and qualitative data were collected concurrently. A cross 
sectional survey design was chosen in order to gather data relating to the standardised numerical 
questionnaires, whilst qualitative interviews were conducted in order to obtain narratives about 
prisoner’s experiences of taking antipsychotic medication.  
The recruitment process is one of the main limitations of this study; this project used a convenience 
sampling strategy rather than random selection, which is likely to have resulted in selection bias 
(Riedel-Heller et al., 2000). Therefore the sample may not be representative of the SMI prison 
population and this may have also led to an overestimation of adherence rates. In order to ascertain 
the representativeness of the sample it would have been worthwhile to compare the demographic 
and clinical data of participants with similar data from the greater prison population. The response 
rate of 79% may also have affected the representativeness of the sample because it is likely that the 
most inherently adherent prisoners agreed to take part in the study. The sample size was not based 
on pre-study considerations of statistical power and it is therefore possible that this oversight 
resulted in an under-powered sample which may have affected the statistical significance of the 
identified associations between variables (Delucchi, 2004).  
The quantitative measures that were used in the study were chosen based on their reported 
strengths in terms of their validity and reliability; however, the problematic nature of clinicians’ 
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assessment of adherence which is previously discussed in this narrative is relevant to this study and 
this approach may have resulted in a further overestimation of adherence rates.  
Although perhaps not ideal; the quantitative and qualitative data were discussed in separate papers 
due to the large amounts of data that required reporting and the health journal restrictions on word 
counts, however a report to the NHS R and D (Gray et al., 2007) and a related discussion paper 
written by the research team and published in “Mental Health Practice” (Bressington et al., 2008) 
combine the results from the data in order to provide a contextual understanding of the 
relationships between variables identified within the quantitative survey (Bryman, 2006).  
The process of analysing the qualitative data is well described and clearly shows how the stages of 
thematic analysis were used to identify categories and themes from the interview data.  But, the 
credibility of the findings are not well discussed in the qualitative paper, it would have been more 
transparent for reflexivity issues to have been outlined as the researchers’ beliefs, values, 
perspectives and professional experience may have influenced the identification and interpretation 
of the themes that emerged from the data (Cresswell and Miller, 2000). A further potential 
limitation of the qualitative element of the study was that it was not practically possible to obtain 
respondent verification of the themes that were identified and this may have also negatively 
impacted on the credibility of the findings (Burnard et al., 2008).  
 
3:3 Study 2: How common is antipsychotic medication non-adherence in an Asian 
population and are targets for interventions different in this context? 
(Bressington et al., 2012a) 
The critical appraisal of this study is also guided by a survey critical appraisal checklist developed by 
Crombie (1996) and adapted for the Oxford Centre for Evidence Medicine (please see appendix 4). 
This study had a clear and clinically relevant focus because it aimed to determine the prevalence of 
non-adherence with antipsychotic medication in patients being treated by the community 
psychiatric nursing (CPN) service in Hong Kong. It also aimed to explore the relationships between 
adherence and beliefs/attitudes towards medication, and identify sociodemographic and clinical 
variables associated with adherence.  
The study involved a large number of patients (584 in total) and had a very high response rate (97%); 
which may have strengthened the representativeness of the sample, but one of the main study 
limitations relates to the convenience sampling strategy which could have introduced selection bias 
(Riedel-Heller et al., 2000). Given that levels of non-adherence with treatment were self-reported, 
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and that data were collected by nurses directly involved in providing clinical care it is additionally 
likely that the patients reported an overly positive picture of their medication taking behaviour. 
These issues could have resulted in underestimating the prevalence of non-adherence in this 
population.   
The study adopts a similar design to that of the prison survey and also used some of the 
standardised assessments that were found to be useful in explaining adherence in prisons, but these 
may not have the degree of specificity required for the very different cultural and clinical setting. 
The measures were chosen based on their reported psychometric properties and availability of 
translated versions. Although they had been translated into Chinese and back-translated into English 
to check for language accuracy this process does not guarantee reliability in a Chinese population 
(Giesinger, 1994). The analysis strategy which involved dichotomising patients as either adherent 
(scoring ≥3) or nonadherent (scoring ≤2) is also arguably another limitation of this study as partial 
and fluctuating adherence may be more commonly observed in clinical practice (Masand et al., 
2009). Therefore it may have been more clinically relevant to utilise the total adherence score as the 
dependent variable rather than polarising the sample into adherent or nonadherent patients.     
Despite using similar approaches to the prison survey, the study was only able to account for 13% of 
the variance in nonadherence (as opposed to 52% of variance in the prison study); suggesting that 
some important additional independent variables have been overlooked.  On reflection the decision 
not to measure treatment satisfaction (using the SWAM; Rofail et al., 2005) which was highly 
significant in explaining adherence in the prison study, may have resulted in the poor explanatory 
power of the final regression model.         
This study only considers quantitative data, because at the time of designing the study the main aim 
was to recruit a large number of patients to try and improve the representativeness of the sample. 
Conducting, transcribing and analysing qualitative interviews in conjunction with the quantitative 
measures with all patients would be rather impractical and too resource intensive, but a small 
sample of patients could have been selected for interview. This lack of qualitative data is a further 
potential study limitation; overall the results from this large quantitative survey provide useful 
information about potential targets for adherence interventions, but if qualitative data relating to 
patients’ experiences of taking medication had been collected, the findings may have been able to 
more accurately contextualise the observed associations between the variables (Cresswell and Plano 
Clark, 2010).  
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In summary, this study provides useful information about the problem of nonadherence with 
antipsychotics in Hong Kong, but the results show that the application of a research methodology 
which is effective in in a western setting is not directly transferrable to a Hong Kong context, and 
therefore further studies are needed to more certainly establish what influences medication taking 
behaviours in Asian populations  
3:4  Study 3: What are the effects of medication management training on staff 
outcomes?  (A systematic review of the literature) 
(Bressington et al., 2013a) 
The critical appraisal of this systematic review is based on a Systematic Review Checklist (CASP, 
2013; appendix 6). The purpose of this study was to identify, and explore the effects of medication 
management staff training studies which aimed to empower mental health clinicians to address non-
adherence with treatment in people with SMI.  The review addressed a clearly focussed question as 
the population, intervention and study outcomes are well defined. The review aimed to include a 
broad range of study designs in order to answer the review question; however, due to a limited 
amount of studies being identified from the search only uncontrolled quantitative studies were 
included in the review. The inclusion of studies only written in English may have resulted in 
important studies that were written in other languages being overlooked and also presents a 
question about the generalisability of the findings beyond English speaking countries (Moher et al., 
1999).  The process of searching the databases is well-described and relatively thorough which 
should have ensured that all of the important and relevant published studies were included in the 
review. But, on reflection it would have been beneficial and more comprehensive to have also 
searched for unpublished studies via clinical trial registration databases.   
Arguably, due to the lack of comparison groups in the included studies it may have been more 
appropriate to conduct a narrative review rather than calculate effects sizes for comparison 
purposes; particularly as the educational and clinical relevance of the individual effect sizes is 
unclear due to the heterogeneity of outcome measures used (Blettner et al., 1999). However, as the 
high degree of observed heterogeneity in terms of outcome measures, study populations, length of 
the training interventions and study designs complicates the direct comparison of results, the 
decision to not combine results by meta-analysis seems appropriate.   
Some of the strengths of this review include the transparency of the discussion relating to the 
review limitations, the methodological qualities of the included studies are appropriately assessed 
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using a recognised checklist and the design and the reporting of the study generally adhered to 
PRISMA guidelines (Moher et al., 2009).    
 
3:5 Study 4: How transferrable is medication management training to an Asian 
population and what further modifications to training are required? 
(Bressington et al. 2012b)   
This study is appraised in accordance with the Critical Appraisal Skills Programme Qualitative 
Research Checklist (CASP, 2013a; appendix 5). The aims of this study were clearly stated as the 
specific objectives were to explore changes in Community Mental Health Practitioners’ (CMHP’s) 
understanding as a result of medication management training and gain insight into CMHPs' 
experiences of using the evidence-based medication management approaches in Hong Kong. The 
qualitative study design is an appropriate method to employ in order to meet these aims due to the 
focus on the experiences of practitioners that had received the medication management training 
intervention. The purposive recruitment strategy is suitable for the population being investigated. 
Although reflexivity issues were considered throughout the research process, the selection of the 
clinicians that were chosen for interview was based the research teams interpretations of the 
structure and contents of the concept maps, and this may have resulted in some meaningful 
additional clinician narratives being excluded. 
 
Although not reported in the published paper, qualitative and quantitative data were collected 
concurrently. The quantitative data (which consisted of the KMMCQ pre and post training scores) 
showed a significant improvement in clinicians’ knowledge about medication management 
immediately post training (t= 5.085; p<0.001; 95% CI 7.97, 3.40); however due to the word 
limitations of the journal in which the paper was published and the journal reviewer’s comments 
about maintaining a qualitative focus in the manuscript these results were not reported.  Therefore, 
on reflection the inability to report the quantitative data may have reduced the overall quality of the 
study because it detracts from the completeness of the study and precludes the in-depth contextual 
understanding that can be conveyed by studies that utilise a mixed-methods study design (Cresswell 
and Plano Clark, 2010). Another limitation of this study relates to the difficulties in generalising the 
findings beyond the study population due to the interpretative nature of the approach.    
The process of thematic analysis is sufficiently rigorous and some of the other strengths of this study 
relate to the credibility of the findings; which were strengthened by the processes of peer review of 
the thematic analysis and respondents’ validation of the results (Tong et al., 2007). The effective use 
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of concept maps to prompt narratives and visualise changes in understanding over time is also 
demonstrated by this study, and as previously discussed in this reflective commentary the decision 
to use this relatively novel approach towards qualitative data collection was based upon previous 
research experience and evidence reported by other researchers.  
3:6 Study 5: What is the extent of treatment related metabolic disorders and other 
physical health problems in Hong Kong? 
(Bressington et al., 2013b).   
The critical appraisal of this study is guided by a survey appraisal checklist developed by Crombie 
(1996) and adapted for the Oxford Centre for Evidence Medicine (appendix 4). This descriptive study 
has clearly defined aims: to estimate the prevalence of metabolic syndrome in community dwelling 
patients with SMI in Hong Kong; and to identify the relationships between metabolic syndrome and 
sociodemographic, treatment and lifestyle variables in the study population. The aim of the study is 
clinically relevant due to the lack of evidence about the prevalence of metabolic syndrome in this 
population and the cross sectional design is appropriate to answer the study question.  
Despite this study’s important and unique contribution towards the evidence base, the results need 
to be viewed in light of the numerous study weaknesses. One of the main limitations relates to the 
consecutive recruitment strategy which was not randomised; it involved CMHPs recruiting and 
collecting data from the first 5 patients that they were routinely scheduled to visit, and is therefore 
likely to have introduced an increased risk of selection bias (Kendall, 2003). A randomised 
recruitment strategy may have helped to minimise this risk.  
The HIP (White et al., 2009) physical health screening tool is the primary measure used for data 
collection. CMHPs used this form to assess areas of physical health risk and to collate/record 
biometric data (blood test results etc.) from recent outpatient records. It is likely that obtaining 
blood test results from outpatient records has resulted in a biased sample, as patients who had been 
invited to attend for such tests may have been asked to do so because of clinicians’ concerns about 
their physical health, and therefore are more likely to have developed metabolic syndrome than 
those who had not been invited. Looking back, it would have reduced the potential of bias if we had 
obtained blood samples as part of the study, however there were a number of reasons why we 
decided against this when designing the study: this approach would have resulted in increased 
financial costs; we wanted to reduce the assessment burden for both CMHPs and patients; and we 
aimed to explore the feasibility of CMHPs taking a brokerage approach towards physical health risk 
assessment by using the HIP within routine clinical practice which would usually involve key-workers 
interrogating existing medical records.       
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As the CMHPs collected data this may have resulted in patients self-reporting an overly positive 
picture of their lifestyle and this could account for the lack of associations identified between 
metabolic syndrome and some health behaviours. The sample size is also relatively small for an 
epidemiological study and as it was not guided by a power calculation this may account for the lack 
of statistically significant associations identified between the dependent and independent variables 
(Delucchi, 2004). Some of the strengths of this study include the rigorous data analysis strategy, the 
results are presented in terms of odds ratios/relative risks with confidence intervals and the 
significance of the findings are discussed in terms of clinical relevance.  
In summary, the studies included in this research programme have some methodological 
weaknesses. These often relate to the recruitment strategies utilised, the selection of specific 
quantitative measures, the approaches used to estimate levels of antipsychotic medication 
adherence and the potential lack of statistical power due to the low numbers of participants. These 
study limitations are frequently the result of pragmatic decisions that are necessitated from 
conducting the research in real-world settings with very limited financial resources. Despite these 
imperfections, the results make an important contribution towards the understanding of how 
mental health professionals can help patients to manage their prescribed antipsychotic medication.    
 
4:  Contribution towards knowledge and the need for further research in this area 
 
The published papers included in this research programme have been referenced by other 
researchers 22 times at the time of writing this narrative.  If the findings can be used to help devise 
medication management staff training programmes which result in improved levels of patient 
adherence with antipsychotics it would be a significant clinical development, which may help to 
improve the efficacy of treatment and hence the cost effectiveness of mental health services.   
 
4:1 What do the research programme’s findings tell us about recommendations for practice 
and education?  
The findings from this research programme contribute towards developing a better understanding of 
influences on adherence with treatment which are potential targets for intervention. The results also 
indicate that the cultural and clinical context of treatment is an important consideration when 
developing medication management training interventions for new populations.  
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The prison studies show that treatment satisfaction is related to adherence and counter-intuitively 
the side effect of weight gain was positively associated with adherence. More side effects were also 
reported by prisoners than in general psychiatric settings and despite the absence of legal powers to 
enforce treatment under the Mental Health Act (1983) levels of adherence were better.  Prisoners 
also stated that in the past side effects had resulted in their stopping their treatment and that they 
were presently passively accepting of treatment.  Therefore, in prisons it is important that clinicians 
appreciate that the adverse effects of treatment are less likely to contribute towards negative 
attitudes about medication whilst patients are incarcerated and more clinical emphasis needs to be 
placed on exploring how prisoners will feel about taking medication when demands on their 
functioning change. 
The Hong Kong adherence survey identified that the factors associated with increased adherence 
were: fewer side effects, being prescribed clozapine, lower levels of symptoms and being in receipt 
of state benefits.  The results may relate to concerns about the impact of side effects on 
occupational functioning or service users’ experiences of stigma about mental illness in the 
workplace.   This suggests that interventions should focus on reducing concerns about the adverse 
effects of treatment, particularly when people are working. Focussing medication management 
interventions purely on the “here and now” may result in clinicians failing to predict and prevent 
non-adherence over the longer term. 
 
The results from both the adherence cross-sectional studies also demonstrate that clinical efforts to 
improve adherence should aim to explore patients’ awareness of the need for treatment and require 
less focus on enhancing insight into the illness itself.  The studies show that improved adherence is 
associated with fewer symptoms and the belief that “my antipsychotic medication makes me feel 
better”; suggesting that improving patients’ satisfaction about the efficacy of treatment is a suitable 
target for medication management interventions. 
A systematic review of the literature demonstrated that medication management staff training 
programmes designed to enhance patient adherence with treatment were likely to be effective in 
improving clinician’s outcomes immediately post-training. However, the study showed that there 
was a lack of evidence in terms of transferability of the training to different clinical populations and 
also identified a lack of robustly designed longitudinal studies that measure the durability of 
improvements and explore clinicians’ experiences of delivering the interventions in clinical practice. 
The results also suggest that a shorter duration of training may be effective in terms of improving 
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mental health professionals ‘ability to manage nonadherence and therefore a reduction in training 
time may improve cost-effectiveness.   
The medication management training study shows that the refined medication management training 
programme had a positive effect on clinicians’ understanding and clinical practice. Practitioners felt 
that the programme was mainly transferrable to an Asian population, but required some 
modifications; particularly in relation to the influences of family members and cultural beliefs on 
adherence with treatment. The study demonstrates that the training requires psychopharmacology 
and side effects management content in order to improve clinicians’ confidence when having 
treatment-related discussions with patients, carers or colleagues. The pragmatic approach that is 
adopted due to perceived implementation barriers suggests that clinical supervision and additional 
resources may also be required to improve fidelity to the treatment model.  
As metabolic disorder was found to be highly prevalent in Hong Kong, physical health inequalities for 
people with SMI in this setting are similar to those observed in western countries. The lack of 
association between metabolic syndrome and antipsychotic medications most widely felt to cause 
metabolic disorders may suggest that lifestyle factors are more important in terms of aetiology and 
raises a question about how much focus medication management interventions should have in this 
regard. The findings may indicate that physical health promotion strategies require greater attention 
as part of general mental health clinical practice rather than being a specific focus of medication 
management. However; the Hong Kong concept mapping study demonstrates that patients’ and 
families’ worries about the effects of medication on physical health are a barrier to adherence and 
therefore enhanced physical health screening may address these concerns and provide some 
reassurance about physical safety.  Due to previously published evidence that atypical antipsychotics 
are associated with metabolic disorders, the physical health monitoring policy in the clinical setting 
recommends that only patients receiving this group of drugs require annual screening.  However, as 
our results show that typical antipsychotics were associated with metabolic syndrome this suggests 
a change in local policy is required and that screening should be extended to all people taking 
antipsychotics irrespective of the drug type or group prescribed. 
The results from the series of studies included in this research programme can be synthesised into 
recommendations for the future development of medication management staff training packages 
designed to assist practitioners in managing patients’ non-adherence with antipsychotic medication. 
These recommendations can be categorised into the following three areas: 
32
• Core elements of medication management training - Approaches designed to manage 
antipsychotic non-adherence should aim to work in partnership with patients to facilitate 
informed choice, focus on maintaining therapeutic engagement and avoid 
criticism/coercion.  Assessing and maintaining satisfaction with antipsychotics is key to 
enhancing adherence and medication should be regularly reviewed to ensure efficacy. 
Clinicians should focus on improving patients’ attitudes towards treatment by enhancing 
perceptions about the personal relevance of treatment and by considering the relationship 
between the environmental contexts of treatment and distress associated with 
antipsychotic side effects. Antipsychotic medication management training packages may be 
most effective if they have built in clinical supervision, provide education on 
psychopharmacology/side effects management and place greater emphasis on the longer 
term influences on treatment satisfaction.  
 • Hong Kong specific required modifications for medication management training:   
Professionals require specific teaching to build their skills and confidence when having 
conversations with patients/families about traditional cultural beliefs relating to mental 
illness and antipsychotic treatment.  Medication management interventions in Hong Kong 
should incorporate regular enhanced physical health screening in order to enhance safety 
and satisfaction with treatment over the long term. 
 • Considerations for adaptation of medication management training to other settings: 
Potential barriers to the implementation of interventions should be considered prior to 
designing medication management training. Involving experienced practitioners in the 
design of training would afford them a sense of ownership of the clinical approaches and 
may highlight additional cultural considerations. 
 
The findings from this research programme have also led to the development of a conceptual model 
for long-term antipsychotic medication management which will require testing in future studies 
(appendix 7). The model aims to provide a framework for enhancing long term adherence by 
improving satisfaction with treatment in three areas of medication outcomes (symptoms, side 
effects and physical safety). The overall aim is to manage fluctuating satisfaction across these three 
spheres of outcome within the environmental and therapeutic context of treatment.  A recent 
systematic review of the literature (Barbosa et al., 2012) reports that satisfaction was found to be 
associated with increased levels of adherence and persistence.  This reinforces the view that 
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components of treatment satisfaction may be useful targets for medication management 
interventions rather than a focus on adherence itself.   
 
4:2 What should be the next steps for research in this area? 
 
It is tempting to assume that targets for medication management interventions are universal; whilst 
some evidence was found to support this it is clear that non-adherence and concerns about 
treatment are environmentally bound. The results show that the application of a research 
methodology which is effective in explaining adherence in a western setting is not directly 
transferrable to different cultural contexts, and therefore further studies are needed to more 
certainly establish what influences medication taking behaviours in Asian populations. As adherence 
is unlikely to be static, longitudinal data would help to get a better picture of adherence behaviours 
over time.  
 
The results show that patient and family concerns about physical health may be related to 
adherence, a finding which requires further exploration and presents a question about whether 
previous medication management studies have given due consideration to longer-term concerns 
about treatment and the potential effects of medication on patients’ physical well-being. 
Satisfaction with treatment is closely related to adherence and given the problems associated with 
measuring adherence, future medication management studies could consider utilising satisfaction as 
an alternative primary outcome measure.  
 
The next stage for research in this area is to measure the efficacy of enhanced medication 
management training for an Asian population. The focus of individual patient interventions will be 
based on the “Medication Management Target Model” (appendix 7) and the additional teaching 
content will include strategies for engaging and working with families in addition to enhanced 
physical health management approaches.  In order to establish the effects of the enhanced 
medication management training on patient outcomes, a cluster randomised controlled trial design 
will be utilised. As previous medication management staff training trials have not used active control 
interventions I plan to compare “enhanced medication management training” to a control training 
intervention based on current best practice (standard medication management training) by 
randomising  clinicians in clusters based on the geographical location of their clinical base.  A mixed-
methods approach towards data collection will be utilised where concept mapping and clinicians’ 
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narratives are used to gain a deeper understanding of learning and implementation issues, in 
conjunction with quantitative data relating to patients’ clinical outcomes.   
 
5 Conclusions 
 
Concerns about the adverse effects of treatment that influence adherence are environmentally 
bound.  As influences on medication adherence are different in different settings, staff training 
programmes should place more emphasis on the local context in order to improve efficacy and the 
feasibility of implementation. The outcomes indicate that the modified medication management 
training programme is likely to result in an improvement in mental health professionals’ ability to 
manage antipsychotic nonadherence in Hong Kong. However, the results also show that in this 
setting medication management interventions should have an increased focus on families and 
treatment satisfaction could be a suitable target for interventions. The findings also present a 
question about whether previous medication management studies have given due consideration to 
predicting and managing concerns about the impact of side effects on functioning over the longer 
term and the potential effects of medication on patients’ physical well-being. The outcomes of this 
programme also demonstrate that future medication management training studies need to use 
robust study designs in order to more certainly attribute clinicians’ improvements to the training 
intervention and could consider measuring treatment satisfaction as a primary patient outcome 
measure. 
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 STUDY 3: 
The effects of training mental 
health practitioners in 
medication management to 
address nonadherence – a 
systematic review 
(Published 2013)  
 
 
Research concept map – development and evaluation of a staff training package 
to manage nonadherence with antipsychotic medication 
Medication Management final training recommendations 
Core elements of training:   Interventions to manage antipsychotic non-adherence should aim to work in partnership with patients to facilitate informed choice, focus 
on maintaining therapeutic engagement and avoid criticism/coercion.  Assessing and maintaining satisfaction with antipsychotics is key. Clinicians should focus on 
improving patients’ attitudes towards treatment by enhancing perceptions about personal relevance of treatment and by considering the relationship between the 
environmental contexts of treatment and distress associated with antipsychotic side effects. Antipsychotic medication management training packages may be most 
effective if they have built in clinical supervision, provide education on psychopharmacology/side effects management and place greater emphasis on the longer term 
influences on treatment satisfaction.  
Hong Kong specific required modifications:   Professionals require specific teaching to build skills/confidence when having conversations with patients/families about 
traditional cultural beliefs about mental illness and antipsychotic treatment.  Medication management interventions in Hong Kong should incorporate regular 
enhanced physical health screening in order to enhance safety and satisfaction with treatment over the long term. 
Considerations for adaptation to other settings: Contextual potential barriers to the implementation of interventions should be considered prior to designing 
medication management training. Involving experienced practitioners in the design of training would afford them a sense of ownership of the clinical approaches and 
may highlight additional cultural considerations.  
 
Are influences on adherence different in Hong 
Kong and what are potential targets for clinical 
intervention? Can a similar research design 
explain adherence in Hong Kong? 
RESULTS: Approaches to manage non-adherence improved as a result 
of training and these were also observed at 9 months follow up. The 
interventions were generally transferrable to Hong Kong, but concerns 
about the effects of antipsychotics on physical health, cultural beliefs 
about treatment and influences of family members were an additional 
challenge in this setting, suggesting a required modification of the 
intervention. Interventions were delivered in a pragmatic manner in 
response to perceived implementation barriers. 
 
In Hong Kong adherence is associated with 
medications reported to cause metabolic 
problems and families’ concerns about 
treatment related physical health problems 
seem related to nonadherence; what are the 
extent of these problems in Hong Kong?  
RESULTS: Adherence is 
better than in the 
community despite more 
side effects reported. 
Adherence associated with 
satisfaction with 
treatment, weight gain and 
positive treatment 
attitudes. Prison 
environment influences 
adherence. Interventions 
to improve adherence 
should focus on enhancing 
personal relevance of 
treatment.  Relationships 
with clinicians were felt to 
be related to adherence. 
 
RESULTS: Non-adherence is common. 
Increased adherence is associated with 
positive treatment attitudes, receiving state 
benefits, lower levels of symptoms, and 
fewer side-effects.  Atypical antipsychotics 
are associated with adherence. 
Interventions need to consider how 
adherence may change as social functioning 
improves and interventions should focus on 
enhancing personal relevance of treatment. 
 
2006 
2007 
2008 
2013 
2010 
2012 
2009 
2011 
Which medication management 
staff training interventions have 
iŵproved praĐtitioŶers’ aďility to 
manage nonadherence?  
What are the contents of 
effective staff training packages 
and which research design would 
be useful to adopt in Hong Kong?   
STUDY 1: 
Prison adherence survey – 
qualitative and 
quantitative 
(Published 2008 & 2011)  
  
STUDY 2: 
Hong Kong adherence study 
(Published 2012)  
 
 
RESULTS: Training effective to 
iŵproǀe cliŶiciaŶ’s kŶoǁledge, 
attitudes and skills immediately post 
training.  Lack of follow up data, 
qualitative data and evidence of 
transferability.  Training should be 
delivered over 5 days, provide clinical 
supervision, include side effect 
management and the core elements 
of adherence therapy.  
RESULTS: Metabolic Syndrome is 
highly prevalent. Physical health 
inequalities for people with SMI are 
similar in Hong Kong to western 
countries. Medication management 
interventions should have increased 
focus on physical health in order to 
enhance safety and satisfaction with 
treatment over the long term.  
 
STUDY 5: Hong Kong Physical 
Health Study  
(Published 2013)  
 
STUDY 4: 
Medication Management Hong Kong Staff Training 
evaluation 
 (Published 2012)  
 
Research design, contents and duration of training 
informed by previous results. 
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Appendix 2 - Table 1: Summary of findings and clinical implications (from Bressington et al.,2008) 
Topic Findings Suggested interventions Potential clinical benefits 
Exchanging 
information 
about treatment  
2/3rds of prisoners felt 
they were not given 
enough information 
To provide clear, understandable and 
accurate information about medication 
(potential benefits and adverse effects) 
To minimise potential mistrust in 
services. To aid in maintaining 
collaborative therapeutic 
relationships 
Service 
provision 
Prison routine helpful, but 
inflexibility in routine a 
potential practical barrier 
to adherence. Prisoners 
who had medication 
dispensed on a daily basis 
were more adherent 
The taking of medication should be 
embedded into the daily routine.  
 
The dispensing of medication should not 
be at the same time as other activities (i.e. 
meal times).    
To reduce the likelihood of 
forgetting to take medication and to 
minimise practical barriers.   
Motivation to 
take medication 
 
Prisoners motivated to 
take treatment were 
more adherent 
Assess motivation in terms of: Importance 
of treatment, Confidence to take 
treatment and Satisfaction with treatment. 
To explore motivation so that 
reasons for feeling unmotivated can 
be identified and addressed   
Recognising 
benefits of 
treatment 
 
The idea that: “my 
antipsychotic medication 
makes me feel better” 
was identified as a strong 
predictor of adherence.  
Explore the direct and indirect benefits of 
treatment and ambivalence about taking 
medication. Help the prisoners to consider 
how medication may help them to achieve 
goals. 
 
To help prisoners recognise the 
benefits of treatment and explore 
the natural uncertainty about taking 
long term medication.  
Side effects 
from medication 
(SE’s) 
 
A higher incidence of SE’s 
was identified than in 
community populations, 
the influence of individual 
SE’s may differ in prison 
populations from the 
general population. 
The impact of side effects may be 
environmentally bound. SE’s should be 
assessed and addressed as required. 
Explore the current distress associated 
with SE’s and help the prisoner to consider 
how these SE’s may impact on functioning 
upon release from prison.   
To reduce distress associated with 
SE’s that is likely to negatively 
influence adherence. To 
collaboratively promote adherence 
when released from prison.  
Assessing 
adherence 
 
Prisoners were passively 
accepting of medication, 
however reported 
previous episodes of non-
adherence  
Assess adherence regularly and explore 
past and present reasons for non-
adherence. For professionals to recognise 
that adherence is subject to change over 
time. 
To maintain concordance in the 
relationship. To obtain an accurate 
picture of the prisoners 
participation and minimise non-
adherence upon release.  
Therapeutic 
relationships 
Majority of prisoners felt 
listened to by 
professionals. Lack of time 
during appointments and 
difficulty accessing talking 
treatments were 
identified as areas for 
improvement.   
To maintain therapeutic collaborative 
relationships with prisoners. Where 
possible; to increase the amount of time 
spent with prisoners in appointments and 
increase the provision of psychological 
input.  
To incorporate psychological 
approaches into treatment packages 
so that residual symptoms may be 
managed and so that engagement is 
maintained.  
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Appendix 3 -  Table 2: Systematic review findings 
Topic Findings Implications for Medication Management training 
Duration of 
training 
Longer duration of training resulted in the largest effect sizes. 
But, the additional costs of training may not translate into 
meaningful educational differences; for example, Gray’s 10 
day study results in only a one point gain on a 16 item 
multiple choice questionnaire when compared to Byrne’s 3 
day programme. 
Reduce training length to the minimum that allows for the required 
teaching content to be covered. 3 days is sufficient to deliver the 
adherence therapy approaches (as demonstrated by Byrne’s 
studies) and an additional 2 days is required for 
psychopharmacology and side effects management.   
Content  Training programmes which incorporated clinical supervision 
result in the largest effects sizes, particularly in relation to 
skills. 
Build clinical supervision into the training in order that clinicians can 
reflect on their clinical work, have support in working with 
challenging patients and ground their practice within theoretical 
perspectives.  
Content Psychopharmacology and side effects 
assessment/management content is only included in Gray’s 
10 day programme. However, previous research 
demonstrates that a lack of psychopharmacology knowledge 
contributes towards clinicians’ difficulties addressing non-
adherence and concerns about side effects are likely to result 
in non-adherence.  
Build psychopharmacology and side effects 
assessment/management content into a shorter programme.  
Interventions should aim to consider how patients’ concerns about 
side effects may negatively influence adherence, particularly when 
demands on functioning change or when they are working. 
Content Adherence with treatment is an important focus of 
medication management interventions. All studies used the 
core elements of Kemp et al.’s “compliance therapy” 
approach to explore patients’ beliefs and attitudes towards 
non-adherence in order to help patients recognise the 
benefits of treatment and address concerns about treatment. 
Utilise core elements of compliance/ adherence therapy in order to 
address non-adherence issues. 
Outcome 
measures 
All studies included in the review used repeated quantitative 
measures to determine the knowledge and attitudinal related 
effects of training; these were typically multiple choice 
questionnaires. The measures used were different across 
each study and were not standardised, resulting in 
complications when directly comparing outcomes due to 
heterogeneity.  
Use an outcome measure that has been tested and reported in 
earlier research. The content validity and test-retest reliability of the 
Knowledge about Medication Management Questionnaire 
(KAMMQ; Gray et al., 2004) had been established and as this 
measure also relates to psychopharmacology content this should be 
considered as a potential outcome measure where training will 
involve this content.      
Follow-up 
period 
Only one study (Byrne and Dean, 2011) reported durability of 
clinicians’ improvements over a significant follow-up period. 
As knowledge and skills deteriorated over 6 and 12 months it 
is likely that the other studies overestimate the effects of 
training on clinicians outcomes.    
Utilise a significant follow-up period to explore how understanding 
and clinical practice are affected by training over the longer term. 
Qualitative 
data 
There is a lack of qualitative data that may help gain a deeper 
awareness of how the training influences clinicians’ 
understanding and clinical practice and gain insight into 
clinical implementation issues.  Using only repeated 
quantitative measures of outcome may encourage rote recall 
of facts rather than meaningful learning     
Use a longitudinal case study approach to measure how 
understanding changes over time and explore clinicians’ experiences 
of using interventions in clinical practice. Consider concept mapping 
to measure changes in understanding and prompt discussion about 
how learning is applied to practice.  
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Appendix 4 – Survey Critical Appraisal Questions 
 
 
(Adapted from Crombie (1996); The Pocket Guide to Critical Appraisal; the critical appraisal approach used by 
the Oxford Centre for Evidence Medicine, checklists of the Dutch Cochrane Centre, BMJ editor’s checklists and 
the checklists of the EPPI Centre). 
 
 
1.  Did the study address a clearly focused question / issue? 
 
2.  Is the research method (study design) appropriate for answering the research question? 
 
3.  Is the method of selection of the subjects (employees, teams, divisions, organizations) clearly 
described? 
 
4.  Could the way the sample was obtained introduce (selection) bias? 
 
5.  Was the sample of subjects representative with regard to the population to which the findings will be 
referred? 
 
6.  Was the sample size based on pre-study considerations of statistical power? 
 
7.  Was a satisfactory response rate achieved? 
 
8.  Are the measurements (questionnaires) likely to be valid and reliable? 
 
9.  Was the statistical significance assessed? 
 
10.  Are confidence intervals given for the main results? 
 
11.  Could there be confounding factors that haven’t been accounted for? 
 
12.  Can the results be applied to your organization? 
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Appendix 5: Qualitative Review Checklist Questions 
 
(Adapted from: Critical Appraisal Skills Programme (CASP; 2013a). Qualitative Review Checklist) 
 
1.   Was there a clear statement of aims of the research? 
 
2.   Is a Qualitative methodology appropriate to address the aims of the research? 
 
3.  Was the research design appropriate to address the aims of the research?  
 
4.  Was the recruitment strategy appropriate to the aims of the research? 
 
5.  Was the data collected in a way that addressed the research issue?  
 
6.  Has the relationship between researcher and participants been adequately considered? 
 
7.  Have ethical issues been taken into consideration? 
 
8.   Was the data analysis sufficiently rigorous? 
 
9.  Is there a clear statement of findings? 
 
10.  How valuable is the research? 
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Appendix 6: Systematic review checklist questions 
 
(Adapted from: Critical Appraisal Skills Programme (CASP; 2013). Systematic Review Checklist)  
 
1. Did the review ask a clearly-focused question? 
2. Did the review include the right type of study? 
3. Did the reviewers try to identify all relevant studies? 
4. Did the reviewers assess the quality of the included studies? 
5. If the results of the studies have been combined, was it reasonable to do so? 
6. How are the results presented and what is the main result? 
7. How precise are these results? 
8. Can the results be applied to the local population? 
9. Were all important outcomes considered? 
10. Should policy or practice change as a result of the evidence contained in this review? 
 
52
Appendix 7 
 Medication Management Target Model – Maintaining antipsychotic 
adherence over the longer term  
 
 
SYMPTOMS 
SATISFACTION 
ADHERENCE 
A 
B C 
D E 
F 
The overall aim is to manage fluctuating satisfaction across the three spheres of medication outcomes 
within the environmental context. 
A: Maintain satisfaction with effects of medication on distressing symptoms - Target is to maximise the effects of 
treatment on problematic symptoms and maintain awareness of the need for treatment.  
B: Maintain satisfaction with treatment safety – Target is to monitor physical health and manage emerging health 
problems. 
C: Maintain satisfaction with medication side effects – Target is to assess/manage side effects, empower patients with 
side effect management strategies and predict how concerns about adverse effects may change in accordance with 
varying demands on functioning. 
D, E, F:  Dissatisfaction with any the three spheres of medication outcomes may result in nonadherence and treatment 
failure.    
D
issa
tisfa
ctio
n
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